9.02
Schlusskurs vom Vortag:
$9.42
Offen:
$9.45
24-Stunden-Volumen:
112.31K
Relative Volume:
0.94
Marktkapitalisierung:
$130.05M
Einnahmen:
$166.88M
Nettoeinkommen (Verlust:
$-74.18M
KGV:
-1.7791
EPS:
-5.07
Netto-Cashflow:
$1.14M
1W Leistung:
-0.55%
1M Leistung:
+7.38%
6M Leistung:
-33.68%
1J Leistung:
-64.28%
Anika Therapeutics Inc Stock (ANIK) Company Profile
Firmenname
Anika Therapeutics Inc
Sektor
Telefon
(781) 457-9000
Adresse
32 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie ANIK mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ANIK
Anika Therapeutics Inc
|
9.02 | 135.82M | 166.88M | -74.18M | 1.14M | -5.07 |
![]()
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-17 | Eingeleitet | B. Riley Securities | Buy |
2024-11-01 | Bestätigt | Barrington Research | Outperform |
2023-08-14 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2023-03-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2022-11-09 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2022-10-14 | Fortgesetzt | Stephens | Equal-Weight |
2022-03-09 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2022-03-09 | Herabstufung | Stephens | Overweight → Equal-Weight |
2021-11-16 | Eingeleitet | Stephens | Overweight |
2021-07-16 | Eingeleitet | UBS | Neutral |
2020-12-16 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2020-05-08 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2020-01-21 | Hochstufung | Sidoti | Neutral → Buy |
2020-01-10 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
2019-11-05 | Eingeleitet | BWS Financial | Sell |
2019-09-24 | Bestätigt | Barrington Research | Outperform |
2019-09-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
2019-07-25 | Hochstufung | First Analysis Sec | Neutral → Strong Buy |
2019-02-22 | Herabstufung | First Analysis Sec | Outperform → Neutral |
2019-02-22 | Herabstufung | Sidoti | Buy → Neutral |
2018-07-27 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2018-06-20 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2018-06-20 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
2018-05-04 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2018-02-23 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2018-01-24 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
2017-10-27 | Bestätigt | Barrington Research | Outperform |
2016-05-09 | Hochstufung | Singular Research | BUY - Long-Term → Buy |
2016-04-27 | Herabstufung | Northland Capital | Outperform → Market Perform |
2016-02-26 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
Anika Therapeutics Inc. stock trend outlook and recovery path2025 Short Interest & Community Consensus Picks - newser.com
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
United States Adhesion Barrier Market Set for Explosive Growth: - openPR.com
Can Anika Therapeutics Inc. (AKP) stock sustain double digit ROEJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
Weiss Ratings Reiterates "Sell (E+)" Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat
Orthopedic Digit Implants Market Report 2025-2033, with Profiles of Extremity Medical, Stryker, Zimmer, Smith & Nephew, Depuy, Arthrex, Acumed, Anika Therapeutics, VILEX, and Paragon 28 - Ortho Spine News
Orthopedic Digit Implants Market Report 2025-2033, with - GlobeNewswire
What technical models suggest about Anika Therapeutics Inc.’s comebackM&A Rumor & Stock Portfolio Risk Control - newser.com
Published on: 2025-10-05 06:33:40 - newser.com
Predicting Anika Therapeutics Inc. trend using moving averagesJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Anika Therapeutics Inc. stock trendline breakdownEarnings Recap Report & Fast Gaining Stock Reports - newser.com
Trend analysis for Anika Therapeutics Inc. this weekFed Meeting & Risk Managed Investment Entry Signals - newser.com
Leading vs lagging indicators on Anika Therapeutics Inc. performanceM&A Rumor & Real-Time Sentiment Analysis - newser.com
Analyzing Anika Therapeutics Inc. with multi timeframe chartsMarket Sentiment Report & Community Verified Trade Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock attractive for growth fundsRisk Management & Real-Time Chart Breakout Alerts - newser.com
Using data filters to optimize entry into Anika Therapeutics Inc.New Guidance & High Conviction Investment Ideas - newser.com
Multi factor analysis applied to Anika Therapeutics Inc.M&A Rumor & Safe Investment Capital Preservation Plans - newser.com
Published on: 2025-10-03 01:07:01 - newser.com
How to monitor Anika Therapeutics Inc. with trend dashboardsEarnings Trend Report & High Conviction Investment Ideas - newser.com
What analysts say about Anika Therapeutics Inc stockMean Reversion Trades & Big Gains Small Investment - earlytimes.in
Can T I Global Limited Survive Disruption in Its Core IndustryRSI Overbought/Oversold & Double Digit Trading Ideas - earlytimes.in
What drives Anika Therapeutics Inc stock priceVolume Spike Alerts & Investment Recommendations You Can Trust - earlytimes.in
Published on: 2025-10-03 05:32:20 - earlytimes.in
Is Anika Therapeutics Inc AKP a good long term investmentPortfolio Diversification Tips & Capital Allocation Recommendations - earlytimes.in
Published on: 2025-09-27 05:01:43 - newser.com
What analysts say about Anika Therapeutics Inc AKP stockStop Loss Placement Tips & Exceptional Return Opportunities - Early Times
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Anika Therapeutics Inc. $ANIK Stock Position Reduced by Goldman Sachs Group Inc. - Defense World
Barrington Research Reiterates "Outperform" Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat
Anika Therapeutics (ANIK) Rating Maintained with $15 Target by B - GuruFocus
Will Anika Therapeutics Inc. stock go up soonJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
Barrington Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Finanzdaten der Anika Therapeutics Inc-Aktie (ANIK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anika Therapeutics Inc-Aktie (ANIK) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):